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Control of canine leishmaniasis is an important objective for the benefit of dogs living in or visiting endemic areas
and for public health because of the zoonotic nature of this disease. Resistance or susceptibility to developing
canine leishmaniasis after exposure to Leishmania infantum is primarily determined by the ability of the immune
system to develop an appropriate Th1-dominated specific response to the parasite. For this reason there is a need
for effective canine vaccines that can decrease the number of dogs developing progressive infections. In this study,
we followed the impact of the LiESP/QA-21 canine vaccine (composed of excreted-secreted proteins of L. infantum
and the QA-21 saponin adjuvant), recently launched commercially in Europe, on selected humoral and cellular
immune parameters following an infectious intravenous challenge with L. infantum promastigotes administered
one year after the primary vaccine course. We also followed parasitological parameters to determine the parasitological
status of the challenged dogs. In contrast to controls, vaccinated dogs retained significantly stronger cell-mediated
immune responses against the parasite despite a virulent challenge and had significantly lower mean parasite burdens
at the end of the study, associated with a lower probability of developing active infections. These results confirm that
the immune responses generated by vaccination with LiESP/QA-21 are still effective against an intravenous challenge
one year after the primary vaccine course.Introduction
Canine leishmaniasis (CanL), a complex disease caused
by an inappropriate immune response to infection with
Leishmania spp, remains a significant problem for the
canine population in endemic areas of the world [1]. In
Europe, the endemic area is primarily the Mediterranean
basin, where the Leishmania species responsible is L.
infantum (= L. chagasi of the New World), and transmis-
sion is mostly due to the bite of infected sandflies of the
Phlebotomus (Larroussius) subgenus [1,2].
As the primary route of transmission remains the bite
of infected sandflies, efforts have been made to reduce
the transmission of this disease by use of effective topical
repellents and insecticides. Several have trial data dem-
onstrating good short-term efficacy for the reduction of* Correspondence: david.mcgahie@virbac.com
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unless otherwise stated.the disease incidence, but some evidence suggests that
this may not be sustained over longer periods [3]. Recent
work showed that the risk of eventually developing the
disease over a prolonged period of time was not directly
linked to the level of exposure [4], and further recent
work in Portugal confirms that although field use of
repellent products helpfully reduces the risk of serocon-
version in the dogs at highest risk, this alone is not suffi-
cient to prevent infection [5]. Furthermore, in recent years
it has become increasingly clear that rare non-vector
transmission of the parasite also occurs [6-8]. The use of
repellent products remains a very important tool in the
overall management of the epidemiology of CanL, but
additional control methods are required [9].
The outcome of infection with L. infantum is highly
variable in dogs [10]. It is now generally accepted that
resistance to developing CanL is primarily dependent on
whether the dog develops an appropriate T-helper (Th)Ltd. This is an Open Access article distributed under the terms of the Creative
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parasite [11,12]. Therefore, there is a clear need to be
able to strengthen a dog’s specific immune response in
order to increase the probability that it will correctly
manage the infection and remain healthy. In addition,
appropriate immune control of parasite replication in
turn reduces the reservoir of dogs infectious to naïve
sandflies [13]. It is for this reason that several authors
have expressed the opinion that an effective vaccine
against CanL would be the best control strategy for both
canine and human disease [9,14], and there is a growing
consensus that an ideal control program for CanL is
likely to involve combined use of vaccines with repellent
products to maximize the protection of the dog [15].
In recent years two vaccines have been registered in
Brazil. Both have a primary course consisting of three in-
jections, followed by annual booster injections. Leishmune®
(Zoetis, Brazil) is based on the fucose-mannose ligand of L.
donovani in association with a saponin adjuvant and dem-
onstrated 76% efficacy against disease or death after natural
infection in a field study with evidence of a type 1 im-
mune response being provided by positive intradermal
skin test results [16]. The other vaccine available in
Brazil is LeishTec® (Hertape Calier, Brazil) which uses the
recombinant A2 antigen of L. donovani in association with
a saponin adjuvant, and demonstrated 43% protection
against a culture positive state in an artificial challenge
model [17]. A more recent review noted unpublished data
suggesting 71% efficacy against a culture positive state in a
field study, albeit without the details of the study design
[18]. However, until recently no vaccines were available in
Europe.
The LiESP/QA-21 vaccine (CaniLeish®, Virbac, France),
was launched in Europe in 2011. Data demonstrating the
rapid onset of an appropriate Th1-dominated cellular im-
mune response after use of the LiESP/QA-21 vaccine,
based on specific IFN-γ production in lymphocytes after
in vitro stimulation and an increase in the leishmanicidal
activity of the macrophages of vaccinated dogs, have been
published [19], and it was recently demonstrated that this
profile persists for a full year after vaccination [20]. How-
ever, as the parasite has a tendency to promote a Th2-
dominated profile during infections, it is important to
demonstrate that significant challenge with virulent para-
sites does not reverse the protective immune profile in-
duced by vaccination [21].
This study aimed to assess whether the Th1-dominated
immune profile induced by the LiESP/QA-21 vaccine
could be sustained in the face of an intravenous experi-
mental challenge (even if this challenge took place beyond
the normal time period in which a booster vaccination
should have been administered), to assess the ability of
this response to effectively reduce the number of dogs de-




The Virbac Ethical Committee approval confirms that this
study was carried out in accordance with the G.R.I.C.E.
“Ethical Committee Regulation applied to animal experi-
mentation” guidelines (implemented in France in 2008)
under project number 136.01.
Summary of the study design
This study compared the response of vaccinated and
unvaccinated dogs to an intravenous challenge with L.
infantum. The vaccinated animals had completed the
primary vaccination course one year before the challenge.
The unvaccinated control group had been maintained in
the same conditions during this period. Both groups were
then followed for nearly 1 year post-challenge. The details
are described below.
Animals’ characteristics
Twenty conventional Beagle dogs (10 male and 10
female) aged approximately 6 months old (between
5 months and 3 weeks, and 7 months old on the day of
the first vaccination), were enrolled into this study. They
were evenly assigned to two groups (vaccinated and
control) according to their sex and litter of birth. There
were 5 males and 5 females per group. They were
housed indoor in controlled conditions to avoid any
possible risk of natural infection with L. infantum.
Vaccine and vaccination protocol
The LiESP/QA-21 vaccine is authorised in the European
Union under the trade name CaniLeish® (Virbac, France).
It is composed of purified excreted-secreted proteins of L.
infantum (LiESP), produced by means of a patented cell-
free, serum-free culture system invented by the IRD
(Institut de Recherche pour le Développement) [22], and
adjuvanted with QA-21, a highly purified fraction of the
Quilaja saponaria saponin. Dogs in the vaccinated group
(n = 10) were given one dose of the LiESP/QA-21 vaccine
subcutaneously every 21 days for a total of three doses.
Vaccinations were administered in the interscapular area.
All doses used were formulated at 100 μg ESP and 60 μg
QA-21. This represents the minimum accepted antigen
level in commercially available doses. Each dose was
reconstituted immediately before use in 1 mL 0.9% NaCL
solution.
No further booster vaccinations were given during the
study. These dogs were therefore “overdue” regarding
their booster vaccination requirement at the time of the
challenge which took place one year later. Dogs in the
control group (n = 10) did not receive any vaccination.
Martin et al. Veterinary Research 2014, 45:69 Page 3 of 15
http://www.veterinaryresearch.org/content/45/1/69Artificial challenge of dogs
On week 58 (which was 1 year after the last injection of
the vaccine), all dogs were challenged intravenously with
108.5 infectious L. infantum promastigotes. The challenge
innoculum was prepared as follows:
The original isolate of the strain MON1 ITMAP 263
was from the laboratories of the Institut de Recherche
pour le Développement (IRD). The strain was passaged on
a dog, and after the infection was established the spleen
was removed to prepare a master seed of amastigotes. In
preparation for the challenge, 2 vials of amastigotes were
thawed, and after transformation into promastigotes
underwent 4 amplification passages in Schneider complete
medium at 25–27 °C for 3 days before being checked for
morphology and vivacity to allow the selection of a single
culture for the challenge. Morphological assessment con-
firmed that the parasites were metacyclic promastigotes,
as described in Bates and Rogers [23]. These parasites
were then washed three times in PBS before being pre-
pared as a suspension of 108.5 parasites/mL in PBS. 1 mL
of this solution was administered intravenously in the
cephalic vein.
Analyses and schedule
Bone marrow sampling to assess parasite load
On weeks 58, 73, 81, 90, 98 and 105 the dogs were anaes-
thetized and bone marrow samples were obtained by ster-
nal puncture into citrated tubes. The samples were stored
at −70 °C until use, which was always within one week.
On each occasion real-time quantitative PCR (qPCR)
was performed to assess the parasite load in the bone mar-
row. Beginning at week 81, culture was also performed on
the samples. These techniques were as described below:
qPCR: After lysis, the DNA of each bone marrow sam-
ple was extracted using a silica column (QIAamp DNA
mini kit). A Taqman probe was used to amplify and
quantify a 200 bp fragment of kinetoplast DNA [24].
Dogs were considered as negative when the titre was
inferior to 40 parasites/mL.
Culture isolation: The presence of Leishmania parasites
was determined by parasite growth on biphasic NNN
medium composed of a liquid phase (RPMI medium with
20% FBS) and a solid phase (agar with 10% rabbit blood).
The tubes were incubated at 25–27 °C.
Regular microscopic observation was performed to
determine the presence of parasites. If no parasites were
observed, successive subcultures were realized each week
for three weeks. A sample was considered as positive
when parasites were observed during the seeding or sub-
culture analysis.
Clinical follow-up
Dogs were observed daily to detect any abnormal behavior
or clinical signs or any alteration in their generalwellbeing. They were also fully assessed clinically once per
month, with a specific assessment for signs typically asso-
ciated with CanL (such as weight loss, splenomegaly,
lymphadenopathy, cutaneous lesions, ocular lesions,
digestive disturbances, etc.). On weeks 58, 90, 98 and 105
biochemical analysis (Total protein, Albumin, Globulin,
Albumin/Globulin ratio) and haematological analysis
(White Blood Cell Count, Red Blood Cell Count,
Haematocrit, Haemoglobin levels and Platelet Count)
were also performed.
Serology testing of the humoral immune response
ELISA testing was performed on weeks 58, 73, 90 and 105
to dose the level of IgG1 and IgG2 antibodies to LiESP.
Dogs were considered as negative when the titre was
inferior to 1/450. On each occasion when ELISA testing
was performed, Immunofluorescence testing (IFAT) was
also performed on the same samples to dose the level of
total anti-Leishmania antibodies.
Briefly, the techniques were performed as follows.
ELISA A NUNC Maxisorp plate was coated with 0.1 μg
ESP per well in carbonate buffer for 90 min at 35–37 °C.
Non-specific sites were blocked with PBS-Tween 0.5%-
milk 5% for 90 min at 35–37 °C. Then serial three-fold di-
lutions of the serum to be tested, from 1/150 to 1/12150,
were made in PBS-milk 0.5% buffer and added to the
plate. After 60 min of incubation at 35–37 °C any anti-
bodies fixed to the ESP were revealed with a specific
peroxydase-conjugated polyclonal anti-IgG1 or anti-IgG2
secondary antibody (Bethyl Laboratories, Montgomery,
USA) and ABTS colouration. The titre corresponded to
the first dilution with an optical density at 405 nm inferior
to 0.4. Dogs were considered as negative when the titre
was inferior to 1/450.
IFAT The Fluoleish® kit (BVT, France) was used accord-
ing to the manufacturer’s instructions using serial dilu-
tions of the serum from the 1/100th to 1/12500th. The
titre in this test corresponded to the last dilution where
at least 50% of the parasites display visible fluorescence.
Cellular immune response assays
The three cell-mediated immunity tests, Lymphoblastic
Transformation Test (LTT), IFN-γ Enzyme-Linked
Immunospot Assay (ELISpot) and Canine Macrophage
Leishmanicidal Assay (CMLA) were performed on weeks
58 and 90, and the LTT and ELISpot assays were also
performed on week 105. They were performed as sum-
marised below:
LTT This assay is designed to reveal the ability of the
specific memory T cells produced as a result of vaccin-
ation to proliferate after being exposed to Soluble
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similar to that previously described [19,25,26].
Briefly, heparinized blood samples were fractionated by
centrifugation over lymphocyte separation medium.
PBMCs obtained were incubated at a density of 106 cells/
mL for 5 days (37 °C, 5% CO2) in presence of either
10 μg/mL ConA, or 10 μg/mL SLA, or with medium
alone. The cells were pulsed during the last 24 h with
10 μM 5-bromo-2-deoxyuridine (BrdU), which is incorpo-
rated into the DNA of proliferating cells. BrdU incorpor-
ation was determined with a specific ELISA system (GE
Healthcare, Chalfont St. Giles, UK), using peroxydase-
labelled anti-BrdU antibodies which were in turn detected
by a substrate reaction using 3,3’5,5’-tetramethylbenzidine.
Absorbance values at 450 nm correlate directly to the
amount of DNA synthesis and thereby to the number of
proliferating cells in culture. The results were expressed as
the lymphoproliferation index, which is the ratio of the
mean optical density obtained for the SLA stimulated
samples compared to the mean optical density obtained
for the non-stimulated samples. ConA was used as a posi-
tive control and the medium alone was used as a negative
control.
ELISpot This assay is designed to determine the propor-
tion of T cells that release IFN-γ after stimulation with
SLA in order to quantify the level of stimulation of a
specific Th1 polarity immune memory response. It was
performed in a manner similar to that previously described
[19,27]. Heparinized blood samples were fractionated by
centrifugation over lymphocyte separation medium. The
PBMCs obtained were incubated at a density of 106 cells/
mL for 3 days in multiscreen HTS filter plates (Millipore,
Billerica, USA) previously coated with canine IFN-γ
capture antibody (R&D System, Minneapolis, USA), in
presence of 10 μg/mL ConA, or 10 μg/mL SLA antigens,
or with medium alone, in a humidified 37 °C CO2 incuba-
tor. The quantity of IFN-γ was revealed with a specific
biotinylated antibody and incubation with Streptavidin-AP
and the BCIP/NBT Chromogen (R&D System, Minneapolis,
USA). The number of specific spots was determined by an
automated ELISpot reader. ConA was used as a positive
control and the medium alone was used as a negative con-
trol. The data presented are the number of spots per 2 × 105
cells after stimulation with SLA minus the equivalent value
obtained with the negative control using medium alone.
CMLA This assay is designed to determine the ability of
monocyte-derived canine macrophages to kill Leishmania
parasites in a co-culture system due to the stimulation of
iNOS expression and the resulting production of NO de-
rivatives when the macrophage is exposed to autologous
lymphocytes derived from canine PBMC. It was performed
in a manner similar to that previously described [19,28-30].Briefly, monocytes, separated from lymphocytes by
adherence, were cultured at a density of 2 × 105 cells per
well at 37 °C and 5% CO2 for 6 days in complete RPMI
1640 medium containing 25 mM Hepes.
After 6 days of culture, monocyte-derived macrophages
were infected with stationary growth phase L. infantum
(MCAN/82/GR/LEM 497) promastigotes at a ratio of 1:5
for 5 h; then the cells were washed and fresh medium was
added for 24 h and this point was considered as time zero.
The cells were checked to ensure that greater than 55%
were infected. The infected cells (t0) were washed and
then in each well 2 × 105 macrophages were incubated
alone or in the presence of 105 autologous lymphocytes
for 72 h in complete medium containing additionally
10 mM HEPES and 5 × 10−5 M 2-mercaptoethanol. After
72 h of co-culture, the lymphocytes were then removed by
several gentle washings, the cell free supernatants were
conserved for analysis and the macrophages were fixed in
order to evaluate the leishmanial killing. One part of the
fixed macrophages was stained with Giemsa and the leish-
manicidal activity was determined microscopically by
counting in triplicate the number of intact parasites per
100 cells in the macrophages co-cultured with the
lymphocytes and contrasting this with the number of
intact parasites per 100 cells in the macrophages cul-
tured with the medium alone (no T cells). The differ-
ence between these results is the percentage inhibition
of the parasite index and is expressed as the CMLA
index using the following formula: CMLA index = 100
minus (mean number of amastigotes per macrophage
multiplied by the percentage of infected cells when co-
cultured with lymphocytes)/(mean number of amasti-
gotes per macrophage multiplied by the percentage of
infected cells when cultured without lymphocytes) ×
100.
The other part of the fixed macrophages was used to
evaluate the % of inducible nitric oxide synthase (iNOS)
expression by immunolabelling with NOS specific anti-
bodies, as described previously. Briefly, the cells were in-
cubated with rabbit polyclonal antibodies directed against
NOS at a dilution of 1:100 in PBS for 1 h at 4 °C, followed
by 3 washes in PBS, then the binding of the antibody was
revealed by use of a labelled anti-rabbit IgG in an im-
munofluorescence assay to determine the percentage of
iNOS positive macrophages.
The production of NO2 (involved in the NO cascade)
was determined in the culture supernatants using the
modified Griess reference technique. When evaluating
this leishmanicidal activity test, a result was considered
as successful when the % inhibition of the parasitic index
(CMLA) was associated with the activation of the NO
pathway and directly correlated with a significant in-
crease of iNOS expression and the production of NO
derivatives.
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The dosage of oxidized (GSSG) and reduced (GSH)
forms of glutathione (redox ratio) was performed on
weeks 58, 73, 90 and 105. The red blood cells con-
tained in a whole blood sample were purified and
frozen at −70 °C. After their lysis, the supernatant was
collected, diluted at 1/30 in 10 nM phosphate buffer
and both GSH and GSSG levels were measured by the
glutathione reductase enzyme recycling and modified
method [31].
Briefly, the dosing of GSH was carried out by adding S-
transferase-glutathione with 1-chloro-2.4dinitrobenzene
which transforms the GSH into S-(2.4 dinitrophenyl)
glutathione [32]. The dosing of GSSG was carried out with
glutathione reductase which reduces GSSG to the sulf-
hydryl form (GSH) in presence of NADPH, H + as co-
factor [33].
The sample was then treated with 1-fluoro-2.4-dini-
trobenze and neutralised with KOH containing 3-(N-
morpholino) propanesulfonic acids. The solutions were
then passed through calibrated separation columns.
The activity of the samples, both the GSH and GSSG
retention time and detection, were calculated using an
internal standard curve on a CX4 apparatus (Beckman)
after colorimetric detection using a 5100 A Coulochem
detector. The follow-up of the simultaneous oxidation
state of NADPH,H + was performed by measuring the
decrease of its absorbance at 340 nm and the redox
state was evaluated on the basis of the GSH/2GSSG
(μmoles/g Hb) ratio potential. All chemicals were ob-
tained from Sigma Co. (France).Figure 1 Classification of the stages of infection used in this study. Para
culture in biphasic media) were used to classify the status of the dog at the eDog status classification
On week 105, the final classification of the dogs was
determined using the results of the parasitological tests
(see Figure 1). This classification system was adapted
from various references in the literature [1,34-36].
Animals which were negative on all tests (PCR negative,
culture negative) were classed as “Leishmania Free”.
Animals which were PCR positive, but culture nega-
tive and otherwise healthy were classed as “subpatent
infection”.
Animals which were PCR positive and culture positive,
with or without clinical signs, were classed as having
“active infection”, which could be symptomatic or
asymptomatic.Statistical analyses
All statistical tests were performed using the SAS v9.1
software, and for all analyses the significance threshold
was set at p = 0.05.
Assessments were performed by use of linear mixed-
effects models and by non-parametrical means compari-
son tests as appropriate. The dogs’ status classification on
week 105 was compared by treatment group using a Fish-
er’s exact test.
Results
Parasitological status at the completion of the study
On week 105, at the completion of the study, the classi-
fication of the dogs in each group was determined to be
the following:sitological criteria (quantitative PCR targeting the kinetoplast DNA and
nd of the study (week 105) according to the scheme in this figure.
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was subpatently infected, 2 dogs were free from
infection.
Vaccinated group – 3 dogs were actively infected,
7 dogs were free from infection.
These data are represented in Figure 2.
Quantitative PCR
Group data for bone marrow parasite loads are pre-
sented in Figure 3. Mean values were higher in the con-
trol group than in the vaccinated group throughout the
challenge period. On week 105, three vaccinated and
eight control dogs were PCR positive, with a significant
difference between groups (p = 0.026).
Culture
In the control group, seven dogs were culture positive
by week 81, and remained culture positive for the re-
mainder of the study. The other three dogs remained
culture negative at each time point.
In the vaccinated group, five of the dogs were culture
positive on week 81 (the first culture performed after
challenge). Three of these (Dogs V8, V9, V10) remained
culture positive for the remainder of the study. However
one returned to culture negative by week 90 (Dog V6).
The other was culture positive until week 98 (Dog V7).Figure 2 Parasitological status of control and vaccinated dogs over th
the parasitological tests for each dog, and the resulting status at the end o
the culture medium was contaminated, denoted by (c).On week 105 there was contamination in the culture
media for this dog, and so it was not possible to obtain
conclusive results. However, at this time point the dog
had returned to a PCR negative state, which would not
normally be compatible with a positive parasite culture.
See also Figure 2 for the details of each dog.Clinical signs
Both groups of dogs grew normally during the early
period of the study with no differences between them.
The mean weight remained stable in both groups for the
duration of the challenge period.
No adverse events (local or systemic) were reported
after any vaccination.
Three vaccinated dogs presented isolated episodes of
mild to moderate hyperthermia during the challenge
phase of the study (>39.5 °C) unrelated to the time of
the challenge (dog V5 on week 88 and week 100, dog V6
on week 92, and dog V8 on week 105). Two of these
dogs (V5 and V6) had been PCR positive (one had also
been culture positive) and both then returned to be PCR
negative before the hyperthermia episode was recorded.
The other (V8) was actively infected at the time. Three
control dogs (dogs C1, C2 and C6) also presented isolated
episodes of mild to moderate hyperthermia (>39.5 °C), but
always during the 8 weeks that followed the challenge.e course of the study. This figure presents the individual results of










































Figure 3 Geometric means of the bone marrow parasite loads over the course of the study. The bone marrow parasite loads were assessed by
quantitative PCR targeting a 200 bp fragment of the kinetoplast DNA performed on weeks 58 (immediately before the challenge, but one year after
the last vaccination), 73, 81, 90, 98 and 105 (equivalent to 47 weeks after the challenge). The number of parasites per ml of bone marrow could thus
be calculated, and the results are presented as the geometric mean of the number of parasites per ml bone marrow for each group. Samples were
considered as negative if the parasite load was inferior to 40 parasites per ml bone marrow. Error bars represent the SD. *p = 0.026.
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perature between the groups throughout the study.
Due to the duration of the challenge phase of this study,
it was anticipated that significant clinical signs may not
develop in the dogs. However, three dogs in the control
group (dogs C3, C4 and C7) developed skin lesions during
the second half of the challenge period that were consist-
ent with leishmaniasis. All were infected dogs. One dog in
the vaccinated group (V9, the dog with the highest bone
marrow parasite load) developed a greasy seborrhea on
week 105 at the end of the study. No dog developed severe
signs typical of leishmaniasis.
One vaccinated dog (V4) developed a marked popliteal
lymph node hypertrophy 3 weeks after challenge, but
this resolved over the following 3 weeks. This dog was
one of the two to be PCR positive at the first PCR as-
sessment and then negative thereafter. It was assumed
therefore to be due to a strong immune response to the
massive parasite challenge administered.
Biochemical and haematological analyses
After challenge, values for white blood cells and platelets
were slightly lower than the normal range in some dogs
of both groups, but all returned to normal by the end of
the study except in dogs C7 and V8 which displayed
thrombocytopaenia from weeks 90 and 98 respectively.
No abnormal values for red blood cells were detected in
any dog.
There was a slight reduction in the mean albumin/
globulin ratio in both groups from week 58 to week 98
which then stabilized until the end of the study. Threedogs from each group (V2, V8, V9, C4, C8 and C10) had
an albumin/globulin ratio < 0.9 at the end of the study.
No dog had hyperproteinaemia at any point.
There were no significant differences between the two
groups throughout the duration of the study for any
biochemical or haematological parameters.
Serology testing of the humoral immune response
After challenge, there was a boost of the antibody pro-
duction in the vaccinated dogs.
IFAT All dogs were IFAT negative at the time of the
challenge in both groups.
In the vaccinated group 9 of the 10 dogs had serocon-
verted on week 73, and the other dog (V9) was IFAT posi-
tive on week 90. IFAT titres remained less than 4 times
the threshold in dogs that were not actively infected (ran-
ging from 1/200 to 1/500). Only two actively infected (V8
and V10) dogs in the vaccinated group reached titres
greater than 1/1000. However one dog (V7) that became
temporarily actively infected but then blocked the infec-
tion was transiently positive at 1/1000 on week 90 before
returning to 1/200 by week 105 after reverting to a PCR
negative state.
In the control group, 6 of the 7 actively infected dogs
seroconverted with IFAT (on week 90 for 2 dogs and week
105 for the other 4 dogs), with titres ranging from 1/200
to 1/1000. The three dogs that did not progress to active
infection (they were never culture positive) and one single
dog that was actively infected (C8) did not seroconvert
with IFAT. See also Table 1 for details.
Table 1 Anti-L. infantum IgG titres as assessed by IFAT
Group Persistent infection Dog W58 W73 W90 W105
Vaccinated No V1 (−) 1/500 1/200 1/200
V2 (−) 1/200 1/200 1/200
V3 (−) 1/200 1/200 1/200
V4 (−) 1/200 (−) 1/200
V5 (−) 1/200 1/500 1/200
V6 (−) 1/200 1/500 1/500
V7 (−) 1/500 1/1000 1/200
Yes V8 (−) 1/200 1/500 1/2000
V9 (−) (−) 1/200 1/500
V10 (−) 1/500 1/2000 1/2000
Control No C1 (−) (−) (−) (−)
C2 (−) (−) (−) (−)
(Subpatent) C3 (−) (−) (−) (−)
Yes C4 (−) (−) (−) 1/500
C5 (−) (−) 1/1000 1/500
C6 (−) (−) 1/1000 1/200
C7 (−) (−) (−) 1/500
C8 (−) (−) (−) (−)
C9 (−) (−) (−) 1/200
C10 (−) (−) (−) 1/500
The IFAT titre was assessed using a commercially available kit, and the titre
corresponds to the last dilution where at least 50% of the parasites display
visible fluorescence. This table presents the individual titres for each dog over
the course of the study.
Martin et al. Veterinary Research 2014, 45:69 Page 8 of 15
http://www.veterinaryresearch.org/content/45/1/69ELISA 7 of the 10 vaccinated dogs retained, or re-
developed, IgG1 titres against LiESP after challenge
with maximum titres between 1/450 and 1/4050.
None of the control dogs developed detectable anti-
ESP IgG1 titres.
All vaccinated dogs retained or re-developed anti-ESP
IgG2 titres after challenge (range 1/450 to 1/4050). Five
of the control dogs also developed anti-ESP IgG2 titres
(range 1/450 to 1/1350).
IgG1 and IgG2 anti-ESP titres were not correlated
with resistance or susceptibility to the infection.
Cellular immune response assays
LTT The cells of all animals in both vaccinated and
control groups were able to respond effectively to the
non-specific positive control stimulation with ConA. A
comparison of the result in both groups after SLA stimu-
lation at each time point is shown in Figure 4 panel A.
The challenge appeared to result in a non-significant sup-
pression of the mean specific lymphoproliferative ability
in both groups on week 90, but this returned to baseline
in both groups by week 105.
ELISpot The cells of all animals in both vaccinated and
control groups were able to respond effectively to thenon-specific positive control stimulation with ConA.
A comparison of the result in both groups after SLA
stimulation at each time point is shown in Figure 4
panel B. The challenge resulted in a rise in IFN-γ
production in both groups by week 90. In the con-
trol group this had fallen back to levels below base-
line by week 105. In the vaccinated group, the levels
also fell again by week 105, but remained higher
than at baseline and significantly different to the
control group (p = 0.0084).
CMLA In the control group, all dogs were below the
threshold for all three parameters at week 58, and des-
pite a slight rise at week 90 none of the dogs reached
the threshold level (30) for the CMLA index. Three dogs
(C1, C9 and C10) achieved levels of iNOS induction and
NO2 production slightly above the threshold for these
tests on week 90, but in all three cases this was still
lower than the lowest results observed in the vaccinated
group.
In the vaccinated group, all dogs were above the
threshold for all three parameters at week 58 and also at
week 90, with a further rise observed at week 90. Only 3
of the vaccinated dogs (V7, V9 and V10) had CMLA
index results below 40 on week 90, and all three of these
dogs were actively infected at this time point.
The mean values for all three parameters were signifi-
cantly higher in the vaccinated group compared to the
control group both before and after the challenge (p =
0.0002 on both occasions for CMLA, iNOS and also NO2).
A comparison of the results in the 2 groups is shown
in Figure 5.
Redox assay
From 15 weeks post challenge (week 73) the oxidised/
reduced glutathione ratio began to rise in the control
group, but remained stable in the vaccinated group.
The groups were different at baseline, but even when
taking this into account for all future analyses the dif-
ference between groups was highly significant at all
points from week 73 (p ≤ 0.0008). See also Figure 6.
Discussion
Experimental studies using artificial virulent challenge
are difficult and expensive to perform for canine leish-
maniasis. This is due to a combination of factors such as
the highly variable outcome of infection, the long incu-
bation period before active infection is established and
the loss of parasite virulence after long term in vitro cul-
ture that makes it difficult to have large quantities of
standardized challenge inoculum [37].
Nevertheless, such studies are an important step in the
development of any CanL vaccine. They permit the verifi-


















































































































Figure 4 Lymphoproliferation responses and production of IFN-γ after Soluble Leishmania Antigen-specific stimulation. Panel A: Soluble
Leishmania Antigen-specific lymphoproliferation. This assay detects the ability of the specific T cells to proliferate after being exposed for 5 days to
Soluble Leishmania Antigens (SLA). The cells were pulsed during the last 24 h with 10 μM 5-bromo-2-deoxyuridine (BrdU). The lymphoproliferation
index is the ratio of the mean optical density obtained for the SLA stimulated samples compared to the mean optical density obtained for the non-
stimulated samples using peroxydase-labelled anti-BrdU antibodies. This figure presents the results before challenge on week 58 (W58), which was also
one year after the last vaccination, and on weeks 90 and 105. Panel B: ELISpot detection of IFN-γ secreting lymphocytes. This assay detects the ability
of lymphocytes to secrete IFN-γ after 72 h specific stimulation with Soluble Leishmania Antigens (SLA) in coated wells with canine IFN-γ capture
antibody. The clones of cells secreting IFN-γ (or spots) were detected using specific biotinylated antibodies and incubation with Streptavidin-AP and
the BCIP/NBT Chromogen. The data presented here are the number of spots per 2 × 105 cells after stimulation with SLA minus the equivalent value
obtained with the negative control using medium alone. This figure presents the results before challenge on week 58 (W58), which was also one year
after the last vaccination, and on weeks 90 and 105.








































































































































Figure 5 CMLA assay: inhibition of the macrophage parasitic
index, iNOS activity and production of NO derivatives. Week 58
(W58) was 1 year after primary vaccination, but before the intravenous
challenge, and W90 was 32 weeks after the challenge. The macrophages
were infected with L. infantum promastigotes and incubated alone or in
the presence of autologous lymphocytes for 72 h. After this, the
lymphocytes were removed, the cell-free supernatants were conserved
for analysis and the macrophages were fixed in order to evaluate the
leishmanial killing. Panel A is a comparison of the ability of the dogs’
macrophages to inhibit parasite multiplication after interaction with
autologous lymphocytes. The leishmanicidal activity was determined by
counting in triplicate the number of parasites per 100 cells in the
macrophages co-cultured with the lymphocytes and contrasting this
with the macrophages cultured without the lymphocytes. The difference
between these results is the percentage inhibition of the parasite index
and is expressed as the CMLA index. Panel B is a comparison of the rate
of expression of iNOS in the macrophages after 3 days of exposure to
autologous lymphocytes. Fixed macrophages were incubated with rabbit
polyclonal anti-NOS antibodies. Antibody binding was revealed by
labelled anti-rabbit IgG to determine the percentage of iNOS positive
macrophages. Panel C is a comparison of the rate of production of NO
derivatives from the macrophages during co-culture with autologous
lymphocytes. NO2 was determined in the culture supernatants using the
modified Griess technique, providing a correlation with the production
of the short-lived NO radical. When the CMLA, iNOS and NO2
measurements are consistently increased, this provides evidence of a
functional interaction between specific memory lymphocytes and
infected macrophages and indicates an increase of NO-mediated parasite
killing as a result of vaccination.
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http://www.veterinaryresearch.org/content/45/1/69induced by vaccination in a relatively small number of
dogs over a realistic period of time and provide the neces-
sary level of confidence to proceed to natural challenge
studies.
As the dogs in this study were from a single source and
were randomized by sex and litter of birth, host variability
was reduced to a minimum. In addition, the administration
of the same challenge dose from the same batch of parasites
to each dog on the same day by the same route reduced
challenge variability, and allowed the effects of the vaccine
to be studied in highly standardized conditions [38].
Several groups have worked on the development of such
artificial challenge models in dogs [37,39,40]. At the time
when we started this study, very little detailed data were
available and so we had to first validate our own model.
However, 2 in vivo challenge studies using intravenous
metacyclic promastigote administration had previously
been performed with good success using vaccine based on
antigen derived from the same patented method of L.
infantum culture [41,42]. An older study, using only 106
cultured promastigotes of L. chagasi appeared to show a
protective effect of a different canine vaccine [43]. How-
ever a later field study in dogs with the same vaccine
could not demonstrate any difference with placebo [44]. It
is possible that the use of continuously cultured promasti-
gotes with multiple passage steps, and at lower numbers
than we used in our study may have reduced the severity




















Figure 6 Redox status of the vaccinated and control groups throughout the course of the challenge period. The GSH/2GSSG ratio was
determined for each dog using purified frozen red blood cells. After their lysis, the supernatant was collected and both GSH and GSSG levels
were measured by the glutathione reductase enzyme recycling and modified method. The data are presented as the mean ratio between the
reduced (GSH) and oxidised (GSSG) forms in each group with the standard error of the mean. The groups were significantly different at each
time point from week 73.
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http://www.veterinaryresearch.org/content/45/1/69not later replicated in the field study. A more recent study
used L. infantum parasites which were kept virulent by
continuous passage in hamsters [45]. However intraven-
ous challenge with 5 × 106 stationary phase promastigotes
was still insufficient to induce any clinical signs in dogs,
and no conclusions could be drawn on the vaccine effi-
cacy. In a further study using L. infantum passaged
through hamsters to retain virulence, at 5 × 107 promasti-
gotes per dog [46] the majority of dogs in both groups de-
veloped patent clinical signs but the studied vaccine failed
to protect the dogs. Finally, in a study using an intraven-
ous challenge with 108 promastigotes of L. infantum
which went through a small number of culture cycles after
being isolated from the spleen of a dog with leishmaniasis
[47], clinical signs began to appear in the majority of dogs
from week 32 post challenge, and there was a partial pro-
tection effect of the studied vaccine.
From these studies, it was clear that the use of parasites
obtained from a diseased dog, with a minimum number of
passages in culture for the necessary amplification would
maximize the likelihood of establishing an active infection
in the majority of dogs. They also supported the use of the
intravenous route with high parasite doses which had
previously been shown to maximize the probability of pro-
gressive infections within a reasonable time [37,39,41,42],
even if this might carry a risk of underestimating vaccine
efficacy [39] while use of lower challenge doses using
parasites produced by continuous in vitro culture may
overestimate the vaccine efficacy [43,44].
A review published before we established our model
[37] suggested that amastigotes may be slightly more effi-
cient at setting up active infections, but that there wereother factors that may explain this apparent effect. We
therefore chose to use metacyclic promastigotes derived
from amastigotes after the minimum number of amplifica-
tion passages to obtain the required number of parasites.
A more recent study using intravenous administration of
a very similar number of parasites in the amastigote form,
did not appear to lead to a more rapid progression to ac-
tive infection than that observed in the current study [48].
The production of active infection in the majority of
infected animals is in itself is a challenge, as it is clear
from the literature that, due to natural resistance, only
approximately 1/3 of dogs exposed to the levels of natural
challenge commonly found in endemic areas will progress
to active infection, and this may take anything from
several months to several years to occur [1].
The intravenous route of administration is likely to re-
sult in some differences with respect to the establishment
of the infection, as it bypasses the local dermal immune
environment [39]. Additionally, natural infection is pro-
vided by means of sandfly bites, and in that case the para-
site is inoculated along with sandfly salivary proteins as
well as many internal parasite proteins released from the
apoptotic parasites that are also present in the sandfly.
These proteins are known to have immune modulating
activity, and such effects will not be present with an intra-
venous challenge [40,49]. For these reasons, artificial
challenge studies should be viewed as a final in vivo
confirmation of the appropriateness of the immune profile
induced by vaccination before proceeding to more exten-
sive natural challenge studies where the true efficacy of
the vaccine can be measured. Artificial challenge studies,
along with in vitro immune profile studies, can then also
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http://www.veterinaryresearch.org/content/45/1/69support the findings of natural challenge studies per-
formed with the same vaccine [50]. Previous studies had
been performed with small batches of a prototype vaccine
based on LiESP produced using the same patented culture
system but with a different adjuvant. These clearly demon-
strated a protective benefit against natural challenge and
an immunotherapeutic benefit for dogs with CanL [51,52].
However as the commercially available vaccine does not
have the same formulation, it is necessary to assess the
immune profile and protection provided with the final
formulation.
The choice to perform the challenge without providing
the booster was in line with the protocols used in challenge
studies for conventional vaccines to confirm the duration
of immunity (EMEA Note for guidance: “Duration of Pro-
tection Achieved by Veterinary Vaccines” EMEA/CVMP/
682/99-Final). However, due to the prolonged incubation
time of this disease, the impact of the vaccine was still be-
ing assessed nearly a full year after the end of the proposed
duration of immunity. In this way a “worst case scenario”
was effectively being tested where the immune system was
being required to respond over a prolonged period of time
based on priming received a full year before the initial
challenge.
Regarding the humoral response data, dogs in the con-
trol group behaved very much in line with what was ob-
served in previous studies [53,54]. Dogs seroconverted
(IFAT or ELISA) only after the dog had become both PCR
and culture positive. By contrast, in the vaccinated group
seroconversion with IFAT and ELISA was evident at low
to moderate levels by the first post-challenge assessment,
unrelated to the infection status. It is interesting to note
that the three dogs in the vaccinated group that developed
active infection were seronegative for anti-ESP IgG2 at the
time of challenge, whereas 5 of the 7 resistant dogs were
seropositive. Additionally, the dog in the vaccinated group
that was slow to re-seroconvert by IFAT (V9), and the dog
that was slow to re-seroconvert by ELISA (V8) both devel-
oped active infection. In this way, both behaved more like
the control dogs with a slower serological response to
challenge rather than the rapid memory response that
may have been anticipated after vaccination. However it
must also be noted that 2 of the resistant dogs in the vac-
cinated group were seronegative by ELISA at the time of
the challenge (V2 and V4), and that both of these dogs de-
veloped only threshold IFAT titres during the study and
were seronegative by IFAT by week 105, suggesting that
the Th1 cell-mediated profile in their immune response
was strongly dominant and that the rapid control of the
parasite by this means avoided significant stimulation of
the humoral response. As a result, great care should be
taken when trying to interpret the significance of an indi-
vidual dog’s serological results in response to a challenge
after vaccination. It is not possible to use serologicalresponses to predict the effectiveness of the vaccination in
an individual dog.
The cell-mediated immunity parameters provided an-
other set of important information during the challenge
period. Although the differences were non-significant, it
appeared that the intravenous challenge received sup-
pressed the ability of the lymphocytes to replicate on week
90 in the majority of the dogs, and this is in line with pre-
viously reported data [55,56]. Likewise the temporary high
peak of IFN-γ production at week 90 as a result of the
challenge, most notable in the vaccinated group, was also
in line with previously reported data [12,57,58]. In the
control group, the return to baseline for the lymphoprolif-
eration index with IFN-γ production at or below baseline
levels is likely to be due to specific T-cell exhaustion in
the majority of the dogs after a prolonged but ineffective
attempt to control the parasite [55]. By contrast, the
recovery of L. infantum-specific T-cell proliferation in the
vaccinated group with the ability produce IFN-γ is prob-
ably because in the majority of the dogs the response was
effective. It also confirms that the Th1 profile is not lost
due to challenge.
The CMLA data are of particular interest. The signifi-
cant difference observed between the groups in all param-
eters 1 year after vaccination was retained despite the
challenge. In the vaccinated group, the slight rise observed
in all parameters indicates that during challenge the cap-
ability of the vaccine-induced effector-memory T cells is
retained and is further enhanced by exposure to the para-
site. In the control group, the fact that the minimum and
median values were little changed but that the spread of
the results generally increased probably indicates the var-
ied levels of natural resistance which are brought into play
subsequent to parasite exposure.
The use of the CMLA test in addition to IFN-γ levels
when assessing the immune profile is crucial due to the
complex interplay of cytokines including the potential im-
pact of IL-10 as an inhibitory factor and the role of TNF-α
as a co-factor of IFN-γ in the control of the macrophage
leishmanicidal activity [59]. These cytokine levels could
not all be assessed in this study. While it may have been
interesting to have looked at the IFN-γ/IL-10 ratio, the
positive results obtained in our CMLA assay clearly con-
firm that the dominant effect of macrophage activators
such as IFN-γ is not abolished by a lack of TNF-α or an
excess of IL-10.
Even if the parameters used to measure the immune
profile confirm that during challenge the vaccine is still
able to influence the immune system in the correct way,
the primary outcome measure assessed in this study was
the parasitological status. The main reason for the use of a
CanL vaccine is to reduce the progression to an active in-
fection after exposure to the parasite – the initial infection
is introduced mechanically by means of a sandfly bite.
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http://www.veterinaryresearch.org/content/45/1/69In this study we observed that the two groups behaved
quite differently. In agreement with previously published
findings, once dogs in the control group developed active
infection this was invariably progressive [34], resulting in
the continued rise of the mean bone marrow parasite load
observed in this group over the course of the study. This
can be contrasted with the vaccinated group, where two
of the five dogs which had active infection on week 81 (V6
and V7) reverted to a PCR-negative state by the end of the
study. This scenario is thought to be highly improbable
under normal circumstances in unvaccinated dogs, but
confirms that even when challenge levels are extreme
enough to overcome natural levels of resistance the vac-
cine is able to alter the otherwise inevitable progressive
nature of a heavy parasite burden and allow the dog to
control the infection. In addition, at the end of the study 2
of the 3 vaccinated dogs which remained actively infected
were experiencing falling parasite loads, and falling or
stable IFAT titres (V8 and V10). This may suggest that
they were also beginning to control their parasite burdens.
It would have been interesting to follow these dogs for
longer, or to observe the impact of a booster injection. It
can also be noted that dog C6 experienced a notable drop
in the IFAT titre at the end of the study. It is possible that
in even rarer cases dogs whose natural resistance is over-
come due to the high challenge levels used could eventu-
ally control the infection.
High parasite burdens have been associated with higher
infectivity to sandflies, and therefore a greater contribu-
tion to the local epidemiology of the disease and a greater
risk to other dogs and humans [60,61]. Recently, it was
demonstrated that when dogs vaccinated with the LiESP/
QA-21 vaccine do progress to active infection they are
nevertheless still less infective to sandflies than non-
vaccinated dogs in the same state [13]. Therefore, if the
vaccine can reduce the number of dogs that progress to
active infection with a high parasite burden in the first in-
stance, plus provide lower infectivity in those that do pro-
gress, these two benefits will be cumulative in reducing
transmission. In theory, this would be beneficial for both
canine and human health should the vaccine be deployed
on a large scale in an area with significant endemicity.
Finally, in this study we also monitored the redox status
of the dogs. It has been proposed that oxidative stress plays
an important role in the pathogenesis of haemolytic an-
aemia in visceral leishmaniasis [62], and it has also been
suggested that it may play a role in liver and kidney dam-
age due to lipid peroxidation [63]. It has been clearly
shown that as dogs develop symptomatic CanL, oxidative
stress rises. An oxidative burst provoked by the enzyme
NADPH oxidase is typical of the phagocytosis process [64]
and large-scale production of reactive oxygen species such
as superoxide can therefore indicate an ongoing (but inef-
fective) cycle of phagocytosis. Experimental evidencesuggests that the intracellular redox status regulates
various mechanisms of cellular function [65] and that
glutathione participates in the induction and maintenance
of T-cell dependent immune responses [66]. Glutathione
constitutes the first line of the cellular defense mechanism
against oxidative injury and the reduced GSH form is
considered as an important antioxidant modulator for the
immune response during Leishmania immunotherapeutics
(I. Vouldoukis et al., unpublished results, in preparation).
Additionally, it has been demonstrated that the oxidized
GSSG form is strongly toxic to the cells. Therefore, a gluta-
thione redox imbalance has been associated with immune
system dysregulation, which may then indicate that it not
only plays a role in promoting the pathophysiology of the
disease, but also that once animals enter this uncontrolled
state it is progressively more difficult for their immune sys-
tems to control the parasite [67-69]. This may partly ex-
plain the fact that after successful chemotherapy of canine
leishmaniasis the ability to mount an effective Th1-
dominated immune response is once again restored [29].
For this reason, oxidative stress represents an interesting
surrogate marker of the level of dysregulation in the im-
mune system during the control of the infection as well as
an indicator of damage being done to vital tissues. Thus it
is highly desirable to maintain a beneficial cellular redox
equilibrium (GSH/2GSSG ratio < 0.1) during the response
to challenge. In our study, the highly significant difference
in the ratio obtained in the vaccinated dogs compared to
control dogs during the response to challenge confirms the
ability of the protective immune response induced by vac-
cination to efficiently control the parasite whilst maintain-
ing an appropriate redox equilibrium.
Taken together, the results presented in this study are
highly encouraging and confirm that this vaccine is effect-
ive in modulating the immune response to L. infantum
even after intravenous challenge at the limit of the pro-
posed duration of immunity. Such results must now be
confirmed in a larger number of dogs exposed to natural
challenge over a longer period of time in order to assess
the real efficacy of the vaccine.
Conclusion
This study has confirmed that even 1 year after the pri-
mary vaccination course, and without receiving an annual
booster injection, vaccinated dogs are still better able to
manage an intravenous parasite challenge. While control-
ling such a challenge, the immune profile as measured
in vitro remains superior in vaccinated dogs, and their
redox balance remains normal. Consequently, after vac-
cination with LiESP/QA-21 the risk of progression to
active infection is significantly reduced, as is the bone
marrow parasite load, and there is even the possibility to
reverse the course of an initial progression to active
infection.
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